Cedan

Quick links to important sections

Cedan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cedan

Quick Facts About Cedan

Property Description
Active Ingredient Cinnarizine
Form Tablet (oral)
Pharmacological Class Selective Calcium Channel Blocker
General Purpose Stabilization of balance and microcirculation
Origin Synthetic compound

What Type of Medicine is Cedan (Cinnarizine)?

Cedan is a synthetic cerebroactive medicine whose active ingredient is Cinnarizine, which is pharmacologically classified as a selective calcium channel blocker and a Histamine H₁ receptor antagonist. Cinnarizine's dual mechanism is clinically recognized for addressing symptoms related to vascular health and balance. As a trade name for Cinnarizine, Cedan is typically presented as a single-ingredient formulation. This focus on a single agent distinguishes it from other common formulations that may combine Cinnarizine with a second drug. This specific formulation is designed for systemic delivery via the oral route.

Composition and General Purpose of Cedan Tablets

Cedan is typically marketed as a monopreparation tablet intended for oral administration, containing Cinnarizine as the sole therapeutic agent. Cinnarizine is recognized for its ability to modulate calcium ion influx and improve the elasticity of red blood cells, thus enhancing microcirculation and oxygen supply, particularly to the brain. The medicine's general purpose is to help stabilize the balance system and provide relief from dizziness and unsteadiness that occur due to circulatory or inner ear disturbances. A typical scenario involves using the medicine to support equilibrium stability in situations where inner ear function is compromised.

What side effects are possible with Cedan?

Possible Side Effects and Safety Information

The safety profile of Cedan (Cinnarizine) is categorized according to official regulatory standards, grouping adverse reactions by the physiological system affected and their reported frequency. This information is derived exclusively from authoritative government regulatory sources.


Documented Adverse Reactions

Adverse reactions are classified into categories such as Common, Uncommon, and Not Known (for those that cannot be estimated from available data).

Classification Examples of Reactions Affected System-Organ Classes
Common Somnolence (drowsiness), Nausea, Weight Increased Nervous System Disorders, Gastrointestinal Disorders, Investigations
Uncommon Vomiting, Fatigue, Upper Abdominal Pain, Hyperhidrosis Gastrointestinal Disorders, General Disorders, Skin Disorders
Not Known Extrapyramidal Symptoms, Cholestatic Jaundice, Severe Hypersensitivity Nervous System Disorders, Hepatobiliary Disorders, Immune System Disorders

Serious and Contextual Safety Notes

Serious adverse reactions officially documented include Extrapyramidal Symptoms (such as Parkinsonism and tremor) and Cholestatic Jaundice. These effects are generally associated with the Not Known frequency category.

Safety notes specify patterns related to exposure: Somnolence is noted to occur particularly at the start of treatment. In contrast, Extrapyramidal Symptoms are reported as more likely during long-term therapy, especially in older adults.

Population-specific considerations include the need for caution in patients with existing Parkinson’s disease due to the potential to aggravate the condition. Furthermore, the safety of Cinnarizine during pregnancy and lactation has not been established, and its use is not recommended for nursing mothers, according to regulatory texts. Certain substances, such as alcohol, may potentiate the sedative effects of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Cedan (Cinnarizine) is officially documented to primarily affect the central nervous system. Regulatory sources list alterations in consciousness as key manifestations, which may range from somnolence to severe stupor and coma. Other documented signs include vomiting, hypotonia (loss of muscle tone), and extrapyramidal symptoms (involuntary movement disorders). These symptoms are often linked in regulatory text to the drug's anticholinergic activity.

In the event of a suspected overdose, immediate medical attention must be sought. This is a critical instruction because regulatory documents state that no specific antidote is known to exist for Cinnarizine overdose. Management is therefore limited to providing symptomatic and supportive care. Authorities advise contacting a poison control center for the latest recommendations.

The severe profile includes reported deaths following both single and polydrug overdoses. A crucial population-related risk noted in official labeling is the development of seizures in a small number of young children after overdose. While supportive measures may involve the limited use of activated charcoal, immediate professional intervention is mandated due to the potential for life-threatening outcomes.

Therapeutic Uses of Cedan

What Cedan Treats: Main Uses and Benefits

Cedan is commonly used across conditions presenting with acute episodes, offering symptomatic relief that contributes to easing the overall symptom load. It is applied when symptoms create noticeable functional strain and is used to help with symptoms related to physical discomfort, inflammatory states, and systemic imbalance, supporting a multi-symptomatic approach. Its core therapeutic class is relevant for pain, swelling, and fever.


Symptom Relief for Acute Episodes

This medication may be part of symptomatic management within clinical settings that involve acute or disruptive symptom patterns. It is relevant for easing symptoms related to physical discomfort such as headaches, toothaches, muscle aches, and menstrual discomfort, as well as conditions where swelling and fever are present. Cedan is applied when groups of symptoms appear suddenly or fluctuate, and short-term symptomatic assistance is needed.

“It supports general well-being during symptomatic phases by assisting with maintaining functional stability.”


Supportive Benefits for Daily Comfort

Cedan contributes to improved comfort during periods of heightened symptoms by helping to address symptom clusters that may become intense. This supportive role is particularly relevant in conditions where functional stability becomes affected. It is often used during phases when symptoms become more noticeable to reduce the overall symptom load.


Quick Fact: Support for Symptoms Related to Physical Discomfort Cedan is commonly used to help manage mild to moderate pain levels, and may assist with temporary discomfort associated with conditions like colds, flu, and muscle strains.

Regulatory References

  1. NIH MedlinePlus overview of ibuprofen

Eligibility and Restrictions for Use

Cedan’s eligibility is strictly defined by regulatory documents, distinguishing between populations who are prohibited, restricted, or eligible for use.

Absolute Non-Eligibility

Use is absolutely prohibited (contraindicated) for individuals with a known hypersensitivity to Cinnarizine or any of its inactive ingredients. It is also prohibited for patients diagnosed with the inherited metabolic disorder, Porphyria.

Conditional Use and Life-Stage Restrictions

Age: The medicine is generally not recommended for children under 5 years of age. Adults and adolescents (over 12 years) are the standard eligible populations.

Pre-existing Conditions: Caution is mandatory for older adults during prolonged therapy due to an increased risk of developing extrapyramidal symptoms. Patients with Parkinson's Disease should only receive the medicine if the clinical advantages clearly outweigh the risk of aggravating their condition. Furthermore, special care is required for patients with hepatic (liver) or renal (kidney) insufficiency, as specific safety data for these populations are limited.

Pregnancy/Lactation: Use is not advisable in pregnant women and not recommended for mothers who are breastfeeding, as human safety data is not established.

What should I know about interactions with other medicines?

The official regulatory documentation for Cedan (Cinnarizine) strictly defines its interaction profile across pharmacodynamic and procedural domains.

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions: Central Nervous System (CNS) Depressants; Tricyclic Antidepressants; Antimuscarinic Drugs.
Specific interacting medicines (if explicitly listed): Alcohol (documented interaction with a substance).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic Potentiation (additive sedative effects; additive antimuscarinic action); Pharmacokinetic Metabolism (involvement of CYP2D6 in ring hydroxylation).
Timing-based interaction rules (if applicable): Mandatory 4-day separation window prior to dermal reactivity indicators (allergy skin tests).

Official Interaction Statements:

  • Potentiation of Sedative Effects: Co-administration with Central Nervous System Depressants (including tricyclic antidepressants) may potentiate the sedative effects of either agent. The regulatory label also states that concurrent use of alcohol may potentiate the sedative effects of the medicine.
  • Additive Antimuscarinic Action: Sedating antihistamines are officially documented to have an additive antimuscarinic action when combined with other antimuscarinic drugs.
  • Diagnostic Interference Restriction: Due to its antihistamine effect, Cinnarizine may prevent an otherwise positive reaction to dermal reactivity indicators if administered within four days prior to testing.

Connection to the Overall Interaction Profile

Regulatory documentation primarily structures the interaction profile around pharmacodynamic reinforcement of CNS depressant effects and a procedural constraint tied to diagnostic testing. The documentation details the potential for additive sedative effects when used with specific substance classes and mandates a timing separation rule to prevent interference with specific dermal reactivity indicators. The involvement of the CYP2D6 enzyme in the drug's metabolic pathway is also officially noted.

Mechanism of Action

The mechanism of action for Cedan centers on the targeted inhibition of Vascular Endothelial Growth Factor Receptors (VEGFRs), specifically VEGFR-1, -2, and -3 . Cedan functions as a receptor tyrosine kinase inhibitor. By binding to these key receptor proteins, the drug modulates the transmission of signals related to cellular proliferation and function inside the cell, thereby directly interfering with the receptor's activity. This molecular blockade disrupts the angiogenesis signaling pathway, which is the biological process responsible for the formation of new blood vessels. Interrupting this pathway represents the drug's primary mechanistic action, as it inhibits the proliferation and migration of the cells that form the vascular system. The physiological consequence of blocking VEGFRs is a resulting state of reduced nutrient and oxygen supply to the local tissue, which contributes to the drug's overall effect profile through a reduction in the rate of cellular proliferation and modulation of local tissue growth dynamics.

Dosage and Administration Information

How to Use Cedan (Cinnarizine): Official Administration Guidelines

Cedan (Cinnarizine) is an oral medication whose use is governed by established administration guidelines. These guidelines define the correct route, dosing, frequency, and conditions for administration.

Administration Details and Dosage Ranges

The approved route of administration for Cedan tablets is oral (by mouth). The medication is typically taken in divided doses throughout the day.

Main Approved Use Standard Adult Dose Frequency and Schedule Maximum Daily Limit
Disorders of Balance 25 mg Three times daily 225 mg
Motion Sickness 25 mg (initial dose) 30 minutes before travel, then 25 mg every 6 to 8 hours as needed. 225 mg

Key Administration Instructions

  • Timing: The tablets should preferably be taken after meals to help reduce the possibility of gastric irritation.
  • Duration: For acute events like motion sickness, use is temporary. For conditions requiring maintenance, treatment may extend over several weeks or months.
  • Dose Adjustment: Dosage for certain conditions may be increased progressively if deemed necessary, but the total intake must not exceed the 225 mg daily maximum.
  • Pediatric Use: Children aged 5 to 11 years typically use a lower dose of 12.5 mg up to three times daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cedan (Cinnarizine)


Evidence for Use in Dizziness and Vertigo

Research exploring the effects of Cedan has been conducted through short-term, randomized controlled trials (RCTs) and systematic analyses of existing data. These studies were applied in research contexts involving fluctuating or unstable symptoms of dizziness and vertigo, often linked to inner ear disturbances. The adult study populations observed were typically those diagnosed with conditions like Ménière's disease or other causes of vertigo. Studies monitored outcomes related to functional imbalance and the frequency and intensity of vertigo episodes.

Studies report measurements of symptom patterns in the observed populations during the study period, which was typically short, lasting only a few weeks. The findings describe patterns observed in the studies related to changes in patient-reported outcomes describing perceived discomfort and symptom severity. Systematic reviews indicate that findings across the systematic reviews described inconsistency and variability among the study outcomes when compared against placebo or other agents for vestibular symptoms.


Evidence for Use in Motion Sickness Prevention

This part describes the types of acute, single-dose, controlled studies, including laboratory and crossover trials, that examined Cedan's ability to prevent motion-induced symptoms. It details the specific outcomes that researchers tracked, such as the onset of nausea and vomiting, in healthy adult volunteers exposed to motion stimuli.

Controlled trials documented measurements related to the delay and prevention of motion sickness symptoms during acute exposure to movement stimuli. Reports focused on single-dose efficacy assessed over a period of several hours. Studies described patterns related to the consistency of measurements for symptom prevention across various controlled research settings. This evidence contributes to understanding symptom patterns in conditions characterized by acute or disruptive episodes and provides context on its study as a method for symptom prevention.


What Is Still Uncertain About Cedan's Evidence Base

The research landscape for Cedan highlights areas where data are still emerging and where certainty remains low. A significant limitation is the heterogeneity across studies, meaning that the specific causes of the symptoms varied widely among the patients studied. The follow-up durations were often limited, and long-term effects are not fully established by the higher-quality controlled research. Comparative evidence is limited; studies directly comparing Cedan to other treatments are often few. Overall, the research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Cedan (FAQ)


Q: How quickly should I expect to feel the effects of Cedan?

Official information indicates that after taking Cedan, the active ingredient typically reaches its highest level in the bloodstream approximately 2 to 4 hours after administration. This time period reflects when maximum plasma concentrations are generally observed.


Q: How long does Cedan stay in your system?

The time it takes for half of the active ingredient (Cinnarizine) to be eliminated from the body, known as the elimination half-life, is generally reported to range from 4 to 24 hours. This reported time frame provides an indication of how the medication is processed and eliminated by the body.


Q: What should I do if my side effects from Cedan don't go away?

If you experience adverse effects that persist or become bothersome, official documents recommend seeking consultation with a healthcare professional. If there is concern about a severe reaction or potential overdose, seeking immediate symptomatic and supportive care is the standard recommended course.


Q: What is the difference between Cedan and a supplement?

Cedan is a prescription medicine containing the active pharmaceutical ingredient Cinnarizine. Unlike dietary supplements, it has defined medical uses, specific dosage instructions, and is subject to regulatory oversight regarding its approved uses, manufacturing, and distribution.


Q: Why is Cedan only available by prescription?

Cedan is classified as a prescription-only medicine due to its established safety profile, which includes the potential for side effects like drowsiness and the risk of Extrapyramidal Symptoms with prolonged use, especially in older adults. These factors necessitate medical supervision for its use.


Q: What does the patient leaflet say about Cedan's main ingredients?

The main therapeutic ingredient in Cedan is Cinnarizine. Official documentation also lists inactive ingredients, or excipients, such as lactose monohydrate and other common fillers. These components are listed in the full patient information leaflet.


Q: Why is it important not to crush or chew Cedan tablets?

The prescribed method of administration is to take the tablets whole by mouth. Altering the tablet by crushing or chewing is not the instructed route of use and can disrupt the intended release of the medicine in the body, which may affect its performance.


Q: Does Cedan make you feel tired or sleepy?

Yes, regulatory documents list Somnolence (drowsiness or sleepiness) as a Common side effect. It is important to know that this effect is especially noted to occur when treatment is first started.


Q: What happens if I take two doses of Cedan too close together?

Taking a dose significantly higher than prescribed may result in symptoms of overdose. Official information states that these symptoms can include drowsiness, vomiting, low muscle tone (hypotonia), and stupor.


Q: Are there any specific foods or drinks I need to avoid while on Cedan?

Official regulatory information specifically states that concurrent use of alcohol should be avoided because it may increase the sedative (sleep-inducing) effects of the medicine.


Q: Can Cedan affect my ability to drive?

Yes, because Cedan may cause drowsiness, especially when treatment begins. Patients who experience this effect are advised in official warnings to avoid driving or operating machinery.


Q: Is Cedan considered a long-term medication?

For acute situations like preventing motion sickness, use is generally temporary. However, for conditions requiring maintenance therapy, official documentation notes that treatment may extend over several weeks or months under medical guidance.


Q: What common side effects are usually temporary when starting Cedan?

Of the documented side effects, Somnolence (drowsiness) is the most common one that is explicitly noted in official information to occur specifically at the start of treatment.


Q: Are there any known long-term effects of taking Cedan?

Yes, a serious adverse reaction known as Extrapyramidal Symptoms (which includes involuntary movements like Parkinsonism and tremor) is documented. This effect is reported as more likely to occur during long-term therapy, particularly in older adults.


Q: What should I tell my doctor about before starting Cedan?

Before starting Cedan, official documents advise informing your doctor if you have a known hypersensitivity (allergy) to the drug or any of its ingredients, or if you have the metabolic disorder Porphyria. Caution is advised if you have Parkinson's disease, as the medication may potentially aggravate this condition.


Q: Are there any known drug-herb interactions with Cedan?

Regulatory documentation specifically addresses interactions with other medicinal products (like CNS depressants) and with alcohol. Information regarding specific interactions with herbal supplements is not generally addressed in the official product label.


Q: Does Cedan cause stomach upset in a lot of users?

Official information lists Nausea as a Common side effect. To help mitigate the possibility of gastric irritation or stomach upset, official guidelines suggest taking the tablets after meals.


Q: Is it true that Cedan affects brain chemistry?

Yes. Cedan is pharmacologically classified as a Histamine H₁ receptor antagonist, and its mechanism involves action on the Central Nervous System (CNS). This action is associated with documented effects such as drowsiness.


Q: How long until the side effects of Cedan typically start to appear?

The most common side effect reported, Somnolence (drowsiness), is specifically noted in regulatory information to occur at the start of treatment.


Q: Do people commonly report headaches with Cedan?

Official reports of adverse drug reactions do not list headache in the most common or uncommon categories of side effects that were observed in studies or post-marketing experience for this drug.


Q: What is the shelf life of Cedan tablets?

The stated shelf life for the tablets, when stored strictly according to the packaging instructions, is typically 2 years (24 months).


Q: Does Cedan need to be refrigerated?

No, official storage guidelines instruct that the tablets must be stored at a temperature that does not exceed 30 C and must be kept protected from light. Refrigeration is not typically specified as a requirement.


Q: Are there studies comparing Cedan to a placebo?

Yes, research exploring the effects of Cedan has been conducted through short-term, randomized controlled trials (RCTs). These types of studies often use a placebo group to help assess the medicine's effects.


Q: Is it possible to be allergic to an ingredient in Cedan?

Yes, use of Cedan is absolutely prohibited (contraindicated) if you have a known hypersensitivity to the active ingredient, Cinnarizine, or any of the inactive ingredients (excipients) in the tablet.


Q: Is there a recommended time of day to take Cedan?

Official instructions recommend that the tablets should preferably be taken after meals. The medication is generally taken in divided doses throughout the day as prescribed, rather than at one fixed time.

How should Cedan be stored and disposed of?

Storage Requirements

Cedan tablets must be stored strictly according to the conditions specified on the regulatory label to maintain product quality and labeled shelf-life. The tablets must be stored at a temperature that does not exceed 30 C and must be kept protected from light. The medicine must be kept in the original packaging until use. As a universal safety measure, the product must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Cedan must be disposed of in line with local regulations for medicinal waste. It is mandatory to use a formal drug take-back program or facility when possible. The medicine must not be thrown into the household trash or emptied into drains, wastewater, or toilets, as required by environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cedan found in:

A-Z Index: